Stifel analyst Rick Wise reiterated a Buy rating and $670.00 price target on Intuitive Surgical (NASDAQ: ISRG).

The analyst commented, "To us, Intuitive's 1Q26 earnings results checked all the key performance boxes and emphasize the company's compelling 2026 outlook. Key drivers this quarter included: (1) procedure growth fundamentals clearly remain healthy as generalsurgery utilization helped support ~16% procedure growth, nicely exceeding Stifel/ consensus 14%/14.5% projections; (2) the DV5 upgrade cycle is helping drive robust overall system revenue growth, up ~25% in the quarter despite challenging China and Japan operating-environments; (3) the company's cost-reduction-initiatives are helping drive considerable COGS (+18% y/y) and operating leverage (+10% y/y) with 1Q26 revenue-growth increasing 23%. Two products that were formerly margin headwinds, DV5 and Ion, have made considerable margin improvement progress. Taken together, all these factors are helping push ISRG 2026 guidance higher, and in turn, helping move our numbers higher as well. Bottom line: As Intuitive management indicated, the key factors that drove excellent 2025 performance appear sustainable and are helping contribute to strong 2026 results."

For an analyst ratings summary and ratings history on Intuitive Surgical click here. For more ratings news on Intuitive Surgical click here.

Shares of Intuitive Surgical closed at $451.29 yesterday.